Since our analysis identified two sodium-coupled neutral amino acid transporters (SNAT) encoded by Slc38a1 and Slc38a2 as possible markers of all DCs or of conventional DCs, respectively, it will be interesting to expand the latest findings on SLC38A2 function in cDC1 and anti-tumor immunity (45) to other disease models and to cDC2s. This evidence concerns the gene SLC38A1 and neoplasm.